JAKs Are Better? Oral Inhibitors Could Beat Injected Biologics In RA
This article was originally published in The Pink Sheet Daily
Executive Summary
Class is gaining strength in other indications, too.
You may also be interested in...
Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift
Pfizer retains its lead in race to bring a novel oral RA drug to market
Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift
Pfizer retains its lead in race to bring a novel oral RA drug to market
JAK Inhibitors Could Face Scrutiny Over Cholesterol Effects
As positive efficacy data rolls in for the janus kinase inhibitors in rheumatoid arthritis, like Pfizer’s Phase III tasocitinib, elevated lipid levels are emerging as an issue worth keeping an eye on.